HemOnc Today, July 25, 2016
Derek Raghavan, MD, PhD
I enjoyed this year’s ASCO Annual Meeting.
The program committee has finally taken very seriously the entreaties from Lowell E. Schnipper, MD, and the gang, incorporating an assessment of value into programmatic content. I had the honor of acting as a value discussant for several strong presentations on the use of taxanes in the prostate cancer oral abstract session, and I was pleased to see that the presentations truly advanced our state of the art.